Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells

doi:10.1016/j.biomaterials.2014.10.018

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells
	Sun, Rong 3; Liu, Yang 4,5; Li, Shi-Yong 4,5; Shen, Song 4,5; Du, Xiao-Jiao 4,5; Xu, Cong-Fei 3; Cao, Zhi-Ting 3; Bao, Yan 4,5; Zhu, Yan-Hua 4,5; Li, Ya-Ping2
刊名	BIOMATERIALS
	2015-01
卷号	37 页码:405-414
关键词	Cancer stem cell All-trans-retinoic acid Doxorubicin Combination therapy Co-delivery
ISSN号	0142-9612
DOI	10.1016/j.biomaterials.2014.10.018
文献子类	Article
英文摘要	Combination treatment through simultaneous delivery of two or more drugs with nanoparticles has been demonstrated to be an elegant and efficient approach for cancer therapy. Herein, we employ a combination therapy for eliminating both the bulk tumor cells and the rare cancer stem cells (CSCs) that have a high self-renewal capacity and play a critical role in cancer treatment failure. All-trans-retinoic acid (ATRA), a powerful differentiation agent of cancer stem cells and the clinically widely used chemotherapy agent doxorubicin (DOX) are simultaneously encapsulated in the same nanoparticle by a single emulsion method. It is demonstrated that ATRA and DOX simultaneous delivery-based therapy can efficiently deliver the drugs to both non-CSCs and CSCs to differentiate and kill the cancer cells. Differentiation of CSCs into non-CSCs can reduce their self-renewal capacity and increase their sensitivity to chemotherapy; with the combined therapy, a significantly improved anti-cancer effect is demonstrated. Administration of this combinational drug delivery system can markedly augment the enrichment of drugs both in tumor tissues and cancer stem cells, prodigiously enhancing the suppression of tumor growth while reduce the incidence of CSC in a synergistic manner. (C) 2014 Elsevier Ltd. All rights reserved.
资助项目	National Basic Research Program of China[2010CB934001] ; National Basic Research Program of China[2013CB933900] ; National Basic Research Program of China[2012CB932500] ; National Natural Science Foundation of China[31470965] ; National Natural Science Foundation of China[51125012] ; National Natural Science Foundation of China[51390482] ; State Key Laboratory of Supramolecular Structure and Materials[sklssm201413]
WOS关键词	ANTI-ABCG2 MONOCLONAL-ANTIBODY ; TUMOR-INITIATING CELLS ; DRUG-RESISTANCE ; POLYMERIC MICELLES ; MULTIPLE-MYELOMA ; NANOPARTICLES ; SIRNA ; DIFFERENTIATION ; NANOMEDICINE ; COMBINATION
WOS研究方向	Engineering ; Materials Science
语种	英语
出版者	ELSEVIER SCI LTD
WOS记录号	WOS:000346541100038
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/276782]
专题	药物制剂研究中心
通讯作者	Wang, Jun
作者单位	1.Univ Sci & Technol China, High Magnet Field Lab CAS, Hefei 230026, Anhui, Peoples R China; 2.Chinese Acad Sci, Ctr Pharmaceut, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 3.Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; 4.Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei 230026, Anhui, Peoples R China; 5.Univ Sci & Technol China, Med Ctr, Hefei 230026, Anhui, Peoples R China;
推荐引用方式 GB/T 7714	Sun, Rong,Liu, Yang,Li, Shi-Yong,et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells[J]. BIOMATERIALS,2015,37:405-414.
APA	Sun, Rong.,Liu, Yang.,Li, Shi-Yong.,Shen, Song.,Du, Xiao-Jiao.,...&Wang, Jun.(2015).Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells.BIOMATERIALS,37,405-414.
MLA	Sun, Rong,et al."Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells".BIOMATERIALS 37(2015):405-414.